Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14992352 | 0.91 | EGLN1 (0.52) | EGLN1ADORA2AGLAHSD17B10LMNA | |
| SCHEMBL627376 | 0.87 | EGLN1 (0.64) | EGLN1ADORA2AGLATSHRHSD17B10 | |
| SCHEMBL623390 | 0.83 | ADORA2A (0.52) | EGLN1ADORA2AGLATSHRHSD17B10 | |
| SCHEMBL628050 | 0.80 | EGLN1 (0.64) | EGLN1ADORA2AGLATSHRHSD17B10 | |
| SCHEMBL627589 | 0.79 | EGLN1 (0.47) | EGLN1ADORA2AGLATSHRHSD17B10 | |
| SCHEMBL14992348 | 0.79 | ADORA2A (0.46) | EGLN1ADORA2ALMNAHTTHPGD | |
| SCHEMBL621412 | 0.79 | EGLN1 (0.79) | EGLN1 | |
| SCHEMBL627008 | 0.78 | HTT (0.50) | EGLN1ADORA2AGLAHSD17B10LMNA | |
| SCHEMBL627435 | 0.78 | EGLN1 (0.50) | EGLN1ADORA2AGLATSHRHSD17B10 | |
| SCHEMBL14992473 | 0.78 | EGLN1 (0.66) | EGLN1ADORA2AGLALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246442-B2 | 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-02 | — | — | US | disclosed |
| US-20180148435-A9 | 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-31 | — | — | US | disclosed |
| US-20170320859-A1 | 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-9573940-B2 | 4-aminoquinazolinyl-2-yl-1-pyrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-21 | — | — | US | disclosed |
| US-20150197507-A1 | 4-Aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-16 | — | — | US | disclosed |
| US-20140309215-A1 | 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARAMCEUTICA NV (BE) | 2014-10-16 | — | — | US | disclosed |
| US-8796263-B2 | 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-05 | — | — | US | disclosed |
| EP-2603502-A1 | 4 - AMINOQUINAZOLIN- 2 - YL - 1 - PYRRAZOLE - 4 - CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2013-06-19 | — | — | EP | disclosed |
| US-20130143871-A1 | 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-06 | — | — | US | disclosed |
| WO-2012021830-A1 | 4 - AMINOQUINAZOLIN- 2 - YL - 1 - PYRRAZOLE - 4 - CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320859-A1 | 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885ADORA2A 3745/4885GLA 1787/4885 |
| US-20180148435-A9 | 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885ADORA2A 3745/4885GLA 1787/4885 |
| US-20140309215-A1 | 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 7/4885ADORA2A 3477/4885GLA 1310/4885 |
| US-20150197507-A1 | 4-Aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885ADORA2A 3619/4885GLA 1393/4885 |
| US-10246442-B2 | 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885ADORA2A 3745/4885GLA 1787/4885 |
| US-20130143871-A1 | 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 7/4885ADORA2A 3477/4885GLA 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.